Enteral Feeding during Indomethacin and Ibuprofen Treatment of a Patent Ductus Arteriosus - 23/07/13
Ductus Arteriosus Feed or Fast with Indomethacin or Ibuprofen (DAFFII) Investigators∗
Abstract |
Objective |
To test the hypothesis that infants who are just being introduced to enteral feedings will advance to full enteral nutrition at a faster rate if they receive “trophic” (15 mL/kg/d) enteral feedings while receiving indomethacin or ibuprofen treatment for patent ductus arteriosus.
Study design |
Infants were eligible for the study if they were 231/7-306/7 weeks' gestation, weighed 401-1250 g at birth, received maximum enteral volumes ≤60 mL/kg/d, and were about to be treated with indomethacin or ibuprofen. A standardized “feeding advance regimen” and guidelines for managing feeding intolerance were followed at each site (N = 13).
Results |
Infants (N = 177, 26.3 ± 1.9 weeks' mean ± SD gestation) were randomized at 6.5 ± 3.9 days to receive “trophic” feeds (“feeding” group, n = 81: indomethacin 80%, ibuprofen 20%) or no feeds (“fasting [nil per os]” group, n = 96: indomethacin 75%, ibuprofen 25%) during the drug administration period. Maximum daily enteral volumes before study entry were 14 ± 15 mL/kg/d. After drug treatment, infants randomized to the “feeding” arm required fewer days to reach the study's feeding volume end point (120 mL/kg/d). Although the enteral feeding end point was reached at an earlier postnatal age, the age at which central venous lines were removed did not differ between the 2 groups. There were no differences between the 2 groups in the incidence of infection, necrotizing enterocolitis, spontaneous intestinal perforation, or other neonatal morbidities.
Conclusion |
Infants required less time to reach the feeding volume end point if they were given “trophic” enteral feedings when they received indomethacin or ibuprofen treatments.
Le texte complet de cet article est disponible en PDF.Keyword : BPD, NEC, npo, PDA
Plan
Supported by Gerber Foundation, National Institutes of Health/National Center for Research Resources-Clinical & Translational Science Institute (UL1 RR024131 and UL1TR000445), and a gift from the Jamie and Bobby Gates Foundation. The authors declare no conflicts of interest. |
|
Registered with ClinicalTrials.gov: NCT00728117. |
Vol 163 - N° 2
P. 406 - août 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?